Cargando…

Ribosomal Antibiotics: Contemporary Challenges

Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial...

Descripción completa

Detalles Bibliográficos
Autores principales: Auerbach-Nevo, Tamar, Baram, David, Bashan, Anat, Belousoff, Matthew, Breiner, Elinor, Davidovich, Chen, Cimicata, Giuseppe, Eyal, Zohar, Halfon, Yehuda, Krupkin, Miri, Matzov, Donna, Metz, Markus, Rufayda, Mruwat, Peretz, Moshe, Pick, Ophir, Pyetan, Erez, Rozenberg, Haim, Shalev-Benami, Moran, Wekselman, Itai, Zarivach, Raz, Zimmerman, Ella, Assis, Nofar, Bloch, Joel, Israeli, Hadar, Kalaora, Rinat, Lim, Lisha, Sade-Falk, Ofir, Shapira, Tal, Taha-Salaime, Leena, Tang, Hua, Yonath, Ada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039520/
https://www.ncbi.nlm.nih.gov/pubmed/27367739
http://dx.doi.org/10.3390/antibiotics5030024
_version_ 1782456073758703616
author Auerbach-Nevo, Tamar
Baram, David
Bashan, Anat
Belousoff, Matthew
Breiner, Elinor
Davidovich, Chen
Cimicata, Giuseppe
Eyal, Zohar
Halfon, Yehuda
Krupkin, Miri
Matzov, Donna
Metz, Markus
Rufayda, Mruwat
Peretz, Moshe
Pick, Ophir
Pyetan, Erez
Rozenberg, Haim
Shalev-Benami, Moran
Wekselman, Itai
Zarivach, Raz
Zimmerman, Ella
Assis, Nofar
Bloch, Joel
Israeli, Hadar
Kalaora, Rinat
Lim, Lisha
Sade-Falk, Ofir
Shapira, Tal
Taha-Salaime, Leena
Tang, Hua
Yonath, Ada
author_facet Auerbach-Nevo, Tamar
Baram, David
Bashan, Anat
Belousoff, Matthew
Breiner, Elinor
Davidovich, Chen
Cimicata, Giuseppe
Eyal, Zohar
Halfon, Yehuda
Krupkin, Miri
Matzov, Donna
Metz, Markus
Rufayda, Mruwat
Peretz, Moshe
Pick, Ophir
Pyetan, Erez
Rozenberg, Haim
Shalev-Benami, Moran
Wekselman, Itai
Zarivach, Raz
Zimmerman, Ella
Assis, Nofar
Bloch, Joel
Israeli, Hadar
Kalaora, Rinat
Lim, Lisha
Sade-Falk, Ofir
Shapira, Tal
Taha-Salaime, Leena
Tang, Hua
Yonath, Ada
author_sort Auerbach-Nevo, Tamar
collection PubMed
description Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification.
format Online
Article
Text
id pubmed-5039520
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50395202016-10-04 Ribosomal Antibiotics: Contemporary Challenges Auerbach-Nevo, Tamar Baram, David Bashan, Anat Belousoff, Matthew Breiner, Elinor Davidovich, Chen Cimicata, Giuseppe Eyal, Zohar Halfon, Yehuda Krupkin, Miri Matzov, Donna Metz, Markus Rufayda, Mruwat Peretz, Moshe Pick, Ophir Pyetan, Erez Rozenberg, Haim Shalev-Benami, Moran Wekselman, Itai Zarivach, Raz Zimmerman, Ella Assis, Nofar Bloch, Joel Israeli, Hadar Kalaora, Rinat Lim, Lisha Sade-Falk, Ofir Shapira, Tal Taha-Salaime, Leena Tang, Hua Yonath, Ada Antibiotics (Basel) Review Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification. MDPI 2016-06-29 /pmc/articles/PMC5039520/ /pubmed/27367739 http://dx.doi.org/10.3390/antibiotics5030024 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Auerbach-Nevo, Tamar
Baram, David
Bashan, Anat
Belousoff, Matthew
Breiner, Elinor
Davidovich, Chen
Cimicata, Giuseppe
Eyal, Zohar
Halfon, Yehuda
Krupkin, Miri
Matzov, Donna
Metz, Markus
Rufayda, Mruwat
Peretz, Moshe
Pick, Ophir
Pyetan, Erez
Rozenberg, Haim
Shalev-Benami, Moran
Wekselman, Itai
Zarivach, Raz
Zimmerman, Ella
Assis, Nofar
Bloch, Joel
Israeli, Hadar
Kalaora, Rinat
Lim, Lisha
Sade-Falk, Ofir
Shapira, Tal
Taha-Salaime, Leena
Tang, Hua
Yonath, Ada
Ribosomal Antibiotics: Contemporary Challenges
title Ribosomal Antibiotics: Contemporary Challenges
title_full Ribosomal Antibiotics: Contemporary Challenges
title_fullStr Ribosomal Antibiotics: Contemporary Challenges
title_full_unstemmed Ribosomal Antibiotics: Contemporary Challenges
title_short Ribosomal Antibiotics: Contemporary Challenges
title_sort ribosomal antibiotics: contemporary challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039520/
https://www.ncbi.nlm.nih.gov/pubmed/27367739
http://dx.doi.org/10.3390/antibiotics5030024
work_keys_str_mv AT auerbachnevotamar ribosomalantibioticscontemporarychallenges
AT baramdavid ribosomalantibioticscontemporarychallenges
AT bashananat ribosomalantibioticscontemporarychallenges
AT belousoffmatthew ribosomalantibioticscontemporarychallenges
AT breinerelinor ribosomalantibioticscontemporarychallenges
AT davidovichchen ribosomalantibioticscontemporarychallenges
AT cimicatagiuseppe ribosomalantibioticscontemporarychallenges
AT eyalzohar ribosomalantibioticscontemporarychallenges
AT halfonyehuda ribosomalantibioticscontemporarychallenges
AT krupkinmiri ribosomalantibioticscontemporarychallenges
AT matzovdonna ribosomalantibioticscontemporarychallenges
AT metzmarkus ribosomalantibioticscontemporarychallenges
AT rufaydamruwat ribosomalantibioticscontemporarychallenges
AT peretzmoshe ribosomalantibioticscontemporarychallenges
AT pickophir ribosomalantibioticscontemporarychallenges
AT pyetanerez ribosomalantibioticscontemporarychallenges
AT rozenberghaim ribosomalantibioticscontemporarychallenges
AT shalevbenamimoran ribosomalantibioticscontemporarychallenges
AT wekselmanitai ribosomalantibioticscontemporarychallenges
AT zarivachraz ribosomalantibioticscontemporarychallenges
AT zimmermanella ribosomalantibioticscontemporarychallenges
AT assisnofar ribosomalantibioticscontemporarychallenges
AT blochjoel ribosomalantibioticscontemporarychallenges
AT israelihadar ribosomalantibioticscontemporarychallenges
AT kalaorarinat ribosomalantibioticscontemporarychallenges
AT limlisha ribosomalantibioticscontemporarychallenges
AT sadefalkofir ribosomalantibioticscontemporarychallenges
AT shapiratal ribosomalantibioticscontemporarychallenges
AT tahasalaimeleena ribosomalantibioticscontemporarychallenges
AT tanghua ribosomalantibioticscontemporarychallenges
AT yonathada ribosomalantibioticscontemporarychallenges